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Abstract
The flavivirus nonstructural protein 3 (NS3) is a protease and helicase, and on the basis of its 
similarity to its homologue encoded by the hepatitis C virus (HCV), the flavivirus NS3 might be a 
promising drug target. Few flavivirus helicase inhibitors have been reported, in part, because few 
specific inhibitors have been identified when nucleic acid unwinding assays have been used to 
screen for helicase inhibitors. To explore the possibility that compounds inhibiting NS3-catalyzed 
ATP hydrolysis might function as antivirals even if they do not inhibit RNA unwinding in vitro, 
we designed a robust dengue virus (DENV) NS3 ATPase assay suitable for high-throughput 
screening. Members of two classes of inhibitory compounds were further tested in DENV 
helicase-catalyzed RNA unwinding assays, assays monitoring HCV helicase action, subgenomic 
DENV replicon assays, and cell viability assays and for their ability to inhibit West Nile virus 
(Kunjin subtype) replication in cells. The first class contained analogues of NIH molecular probe 
ML283, a benzothiazole oligomer derived from the dye primuline, and they also inhibited HCV 
helicase and DENV NS3-catalyzed RNA unwinding. The most intriguing ML283 analogue 
inhibited DENV NS3 with an IC50 value of 500 nM and was active against the DENV replicon. 
The second class contained specific DENV ATPase inhibitors that did not inhibit DENV RNA 
unwinding or reactions catalyzed by HCV helicase. Members of this class contained a 4-
hydroxy-3-(5-methylfuran-2-carbonyl)-2H-pyrrol-5-one scaffold, and about 20 μM of the most 
potent pyrrolone inhibited both DENV replicons and West Nile virus replication in cells by 50%.
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Flaviviruses comprise a genus of positive-sense single-stranded RNA ((+)ssRNA) viruses. 
They include the important human pathogens yellow fever virus (YFV), Japanese 
encephalitis virus (JEV), Dengue virus (DENV), and West Nile virus (WNV). Many of 
these mosquito-borne viruses are endemic in tropical regions. Vaccines exist for only YFV 
and JEV. DENV is probably the most noteworthy human health threat because it infects an 
estimated 390 million people each year, causing “break-bone” fever, an extraordinarily 
painful disease with symptoms ranging from mild fever to a fatal hemorrhagic syndrome.1
The recent development of direct-acting antiviral (DAA) drugs to treat the hepatitis C virus 
(HCV), which is in the same Flaviviridae family as the flaviviruses, suggests that similar 
compounds might be useful to treat flavivirus infections or hemorrhagic fevers.2 DAA 
targets encoded by flaviviruses include the viral structural proteins (capsid protein C, 
membrane protein M, envelope protein E) and nonstructural proteins (NS1, NS2A, NS2B, 
NS3, NS4A, NS4B, and NS5). DAAs have been reported that inhibit the flavivirus capsid 
protein,3 the NS5 polymerase,4 the NS2B-NS3 protease/helicase,5,6 the NS4B protein,7 the 
NS5 guanylyltransferase,8 and the NS5 polymerase.4
NS3 is one of the most thoroughly studied antiviral drug targets, and this work has led to 
approval of several new antiviral drugs to treat HCV.9 NS3 proteins are unlike any others 
found in nature because they combine an N-terminal protease needed for viral polyprotein 
processing with a C-terminal domain functioning as an ATP-fueled RNA helicase. The new 
HCV drugs inhibit the NS3 protease function, but compounds that inhibit the helicase10–13 
and compounds that bind between the helicase and protease domains14 also function as 
antivirals in cell culture.
The viruses in Flaviviridae encode the only known proteins that are both helicases and 
proteases. The helicase portion of these NS3 proteins is composed of two motor domains 
that are similar in all superfamily 1 and 2 helicases and a third domain very different from 
other helicases. ATP binds between the motor domains, and RNA binds between the motor 
domains and domain 3.15 Detailed mechanistic studies have revealed how the NS3 helicase 
moves like an inchworm in a 3′ to 5′ direction along one strand of RNA while actively 
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displacing the complementary strand in an ATP-fueled reaction.10,16 Similar structural15 and 
enzymatic analyses of the DENV helicase suggest that the hepacivirus and flavivirus 
proteins share a similar mechanism of action.
Although they share key similarities, NS3 proteins from the hepacivirus and flavivirus 
genera are also remarkably different. First, NS3 proteases are most active only when 
combined with another viral peptide, but the HCV NS3 protease is activated by HCV 
NS4A,17,18 and flavivirus NS3 is activated by NS2B.19,20 Unlike the analogous NS4A 
protein in HCV, NS2B wraps like a belt around NS3 such that part of the cofactor 
contributes residues to the active site of the protease.21,22 Second, the NS3 helicase and 
protease domains are oriented differently relative to each other in the two genera. In all X-
ray crystal structures reported to date, the HCV NS3 protein folds in a compact 
conformation where the protease domain does not contact the known RNA- or ATP-binding 
sites on the helicase.23 However, the DENV NS3 has been observed twice in more extended 
conformations. In the first observed conformation,19 the DENV protease partially blocks the 
ATP-binding site. In the second conformation, the protease is rotated by about 180° so that 
both ATP and RNA can access the helicase active site.24 These conformations appear to be 
biologically relevant because mutations that affect the flexibility of the helicase–protease 
linker also affect the ability of DENV to replicate in cells.24 Third, the HCV helicase is 
capable of separating both DNA25 and RNA26 duplexes in vitro, but the flavivirus NS3 
clearly prefers RNA in most assays. Finally, unlike the HCV proteins, the flavivirus helicase 
ATP-binding site can also accommodate RNA so that the protein can cleave the terminal 5′ 
phosphate to prepare genomic RNA for capping.25
A few flavivirus NS3 helicase inhibitors have been reported previously.27 Recent examples 
include ivermectin, which was discovered to inhibit the helicase using molecular 
modeling,28 ST-610, which was discovered using assays monitoring DENV cytopathic 
effects,29 and suramin, which was discovered to inhibit DENV by screening compound 
libraries with a molecular beacon-based helicase assay.30 Ndjomou et al.12 also recently 
showed that some compounds resembling NIH molecular probe ML28331 are potent 
inhibitors of DENV NS3-catalyzed ATP hydrolysis. We have therefore designed a new 
DENV helicase assay, optimized the new assay for high-throughput screening, and used the 
assay to analyze a small library of additional ML283 analogues and other compounds. Here, 
we report that some of the more specific ML283 analogues exert an antiviral effect against 
DENV and that another class of helicase inhibitors, which share a pyrrolone scaffold, 
specifically inhibit the ability of DENV NS3 to cleave ATP and DENV and WNV 
replication in cells.
RESULTS
After comparing several different ATPase assay protocols with several different flavivirus 
helicases, we found that the most cost-effective (at ~2.5¢/assay) was a colorimetric 
inorganic phosphate assay using DENV helicase. The recombinant flavivirus helicase we 
found to be most stable in vitro was a truncated enzyme from dengue virus serotype 2 
(TSV01 strain). In this NS3 protein (called NS3h), the protease domain is replaced by 
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thioredoxin to enhance solubility. NS3 residues 171–618 are present, and thioredoxin can be 
removed with enterokinase so the protein can be examined using X-ray crystallography.15,32
The colorimetric assay included poly(U) to mimic the stimulatory effect of RNA binding to 
the helicase (Figure 1A). In this way, compounds that restrict ATP hydrolysis, ATP binding, 
or RNA binding could be discovered. Like all helicases, NS3h hydrolyzes ATP more rapidly 
in the presence of nucleic acids than in their absence. ATP hydrolysis fuels helicase 
movements on RNA. In the procedure for automated HTS, assays were assembled, 
compounds added, and reactions initiated with 3 μL of an MgCl2 solution and terminated 
after 30 min with 50 μL of the Biomol Green reagent (Enzo Life Sciences). Phosphate was 
then determined from absorbance at 620 nm (Figure 1B). The sensitivity of the Biomol 
reagent allowed the assays to be conducted at subsaturating ATP concentrations near the Km 
observed for the enzyme (i.e., 100 μM ATP). At this ATP concentration, compounds that 
either affect the turnover number of the enzyme (kcat) or the affinity of the enzyme for ATP 
(Km) could, in theory, be detected in an HTS.
Under these conditions, pilot screens comparing DMSO and the nonspecific helicase 
inhibitor aurintricarboxylic acid (ATA)11,34 led to excellent Z′ factors (Figure 1C).33 
Concentration–response assays with ATA and other nonspecific helicase inhibitors such as 
suramin11 and titan yellow35 yielded half-maximal inhibitory concentrations similar to those 
reported with other assays with the related NS3h protein from HCV (Figure 1D). The assay 
was also insensitive to DMSO concentrations up to 10% (v/v) (data not shown).
The assay was used to screen a library of 253 compounds that were reported to inhibit other 
helicases. Most of the compounds in this focused helicase inhibitor library were either 
previously reported to inhibit the homologous HCV helicase or the SV40 Tag helicase, or 
they were nucleic acid binding compounds reported to inhibit one or more helicases. When 
tested at 7 μM, only 41 of the compounds inhibited DENV NS3h-catalyzed ATP hydrolysis 
>50% in two separate assays (Figure 2A).
Two sets of hit compounds were selected for further analysis. The first set (Tables 1 and 2) 
were analogues of NIH molecular probe ML283 (compound 13), which was developed to 
target the HCV helicase.31 ML283 and most of its analogues were synthesized from a 
benzothiazole dimer purified from the yellow dye primuline.36 The second set contained 
pyrrolones (Table 3, see the Supporting Information for synthesis). The most potent 
compound in the benzothiazole class (compound 5, Table 1) inhibited DENV NS3h-
catalyzed ATP hydrolysis with a half-maximal inhibitory concentration (IC50) that was 
about 100 times lower than the IC50 observed with the most potent compound in the 
pyrrolone class (compound 26, Table 3).
Representatives of each class of inhibitory compounds were next tested in helicase assays in 
which the ability of the enzyme to separate duplex RNA was monitored (Figure 3A). All of 
the compounds tested from the benzothiazole class also inhibited the ability of DENV NS3h 
to separate an RNA duplex in a concentration-dependent manner, but none of the pyrrolones 
inhibited RNA unwinding (Figure 3C; Tables 1–3). Most of the IC50 values obtained in the 
unwinding assays were similar to the IC50 values obtained in ATPase assays with a few 
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exceptions. About 20 times more of compound 5 was needed to inhibit RNA unwinding to 
the same degree as was needed to inhibit ATP hydrolysis (Table 1), and about 8 times less 
of compound 20 was needed to inhibit RNA unwinding than ATP hydrolysis.
The specificity of each DENV helicase inhibitor was then evaluated by performing the same 
ATPase assay in the presence of HCV helicase instead of DENV helicase. The ability of 
each DENV helicase inhibitor to inhibit HCV helicase-catalyzed DNA and RNA unwinding 
was also evaluated using assays similar to those used for DENV, except that a different 
buffer system was used with HCV helicase because HCV helicase has poor unwinding 
activity at pH 7.5.38,39
None of the pyrrolone compounds inhibited any of the reactions catalyzed by HCV helicase, 
and more of each benzothiazole was needed to inhibit HCV helicase-catalyzed ATP 
hydrolysis than DENV-catalyzed ATP hydrolysis to the same extent (Table 1). When IC50 
values obtained in DENV ATPase assays were compared with IC50 values obtained in 
various HCV helicase assays, the best correlations were between IC50 values obtained in 
HCV DNA unwinding assays (Table 1, column 6) and IC50 values obtained in DENV 
ATPase assays (Table 1, column 3). When these numbers were compared, most of the 
ML283 analogues displayed similar inhibitory potentials for HCV and DENV helicases with 
the noteworthy exception that compounds 5 and 24 were both more active against DENV 
than the HCV helicase (Tables 1 and 2).
For flavivirus helicase inhibitors to be used as molecular probes in cells, they must be 
relatively nontoxic and inhibit viral replication. Compounds in the focused helicase inhibitor 
library were therefore also tested in cell-based assays to determine the effects on cell 
viability and flavivirus replication (Figure 4).
The first set of assays used a subgenomic DENV-2 replicon designed by Whitby et al.41 In 
the DENV-2 replicon, DENV-2 nucleotides 180–2342 are replaced by fusing the first 28 
amino acids of the capsid protein with the Renilla luciferase, ubiquitin, and puromycin N-
acetyltransferase (Purr) genes. An encephalomyocarditis virus internal ribosome entry site is 
also present between the reporter and the NS1 region (Figure 4A). These replicon assays 
measured the ability of 20 μM of each compound in the collection to inhibit Renilla 
luciferase after cells harboring replicons were exposed to compounds for 72 h (Figure 4B, y-
axis). In the second set of assays, the effect of the same compound concentration on BHK 
cell viability was monitored (Figure 4B, x-axis).
At 20 μM, most of the compounds in the collection had some impact on replicon levels. 
About half of the compounds with the highest activity against replicons (>65% inhibition) 
were toxic, meaning that they reduced cell viability and replicon content to a similar degree 
(upper left quadrant, Figure 4B). Many of the compounds with a modest (20–50%) impact 
were in the benzothiazole class (ML283 analogues), and most of these were previously 
reported to have a similarly modest impact on subgenomic HCV replicon levels in Huh7.5 
cells.31,36 Only 22 compounds (9%) inhibited the replicon more than 65% and cell viability 
less than 20% (upper right quadrant, Figure 4B).
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The relatively nontoxic replicon inhibitors included compounds in both the benzothiazole 
and pyrrolone classes. The ability of members of each class to inhibit DENV replicons in a 
concentration-dependent manner was therefore monitored by applying each active 
compound to replicon cells in an eight-point two-fold dilution series starting at 100 μM. 
Compound efficacy was compared with ribavirin and the NS5 inhibitor BG323.8 In these 
concentration–response assays, only one compound in the benzothiazole class inhibited 
replicon content more than 90% (compound 24, Table 2). Like the compounds in Table 1, 
compound 24, also inhibited reactions catalyzed by HCV helicase. For example, 24 inhibited 
HCV helicase-catalyzed RNA unwinding with an IC50 value of 2.0 ± 0.7 μM. None of the 
benzothiazoles were tested against authentic virus because of the limited solubility above 50 
μM.
All of the pyrrolones tested inhibited the DENV replicon in a concentration-dependent 
manner (Table 3). The most potent in cells, compound 25, inhibited both DENV helicase-
catalyzed ATP hydrolysis and the DENV replicon with half-maximal inhibitory 
concentrations of 78 ± 23 and 36 ± 6 μM, respectively (Figure 4C). Each pyrrolone tested 
inhibited cell viability, also, but only at concentrations >50 μM (Figure 4D).
Each of the hits in the pyrrolone series was also tested for its ability to inhibit the replication 
of West Nile virus (Kunjin strain) in BHK cells by examining plaque titers after incubation 
with 50 μM of each compound (Figure 4E). Results paralleled those seen with the DENV 
replicon, with compound 25 lowering plaque-forming units (pfu) to the greatest extent 
(Figure 4E; Table 3). Effects on WNV were concentration-dependent with 22 μM of 
compound 25 exerting a half-maximal inhibitory effect (Figure 4F). In similar experiments, 
exposure of the same WNV-infected cells to 50 μM of BG323 also yielded about 106 pfu of 
West Nile virus at 72 h,8 suggesting that BG323 and compound 25 yield similar antiviral 
effects.
DISCUSSION
Our inspiration for developing helicase inhibitors as drugs comes from the fact that helicase 
inhibitors are now potent antiviral agents that, in some clinical trials, rival many of the drugs 
traditionally used to treat virus infections.42,43 Boehringer Ingelheim44 and Bayer45 
discovered the first antiviral drugs that target the herpes simplex virus helicase. Boehringer 
Ingelheim identified their inhibitors by screening for compounds that inhibit helicase-
catalyzed DNA strand separation. The Bayer compounds were discovered using 
cytoprotection assays.45 The Bayer thiazolylamide compound BAY 57-1293 inhibits 
purified helicase-catalyzed ATP hydrolysis (IC50 = 30 nM), can be used to treat HSV in 
animal models,46,47 and is being tested in humans as the drug pritelivir.48 Astellas Pharma 
Inc. also developed a HSV helicase inhibitor called amenamevir (ASP2151), which inhibits 
helicase-catalyzed ATP hydrolysis (IC50 = 78 nM) and shortens the median time for lesion 
healing.49,50
Helicases are nevertheless challenging drug targets because helicases are difficult to inhibit 
with small molecules and potent inhibitors are often not specific. Many potent helicase 
inhibitors interact with the nucleic acid substrate or highly conserved regions of the helicase 
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motor domains.51 Prior high-throughput screens with DENV helicase have yielded 
inhibitors that were either nucleic acid binding agents2 or nonspecific nucleic acid mimics 
such as suramin30 and aurintricarboxylic acid (ATA).34 Because previous screens for 
flavivirus helicase inhibitors used unwinding assays,2,30 we set out to perform screens using 
an ATPase assay to test the hypothesis that compounds that inhibit helicase-catalyzed ATP 
hydrolysis might function as antivirals even if they do not inhibit the ability of the protein to 
unwind RNA.
The DENV ATPase assay that we have optimized was designed so that it can, in theory, 
detect compounds that inhibit ATP binding or ATP hydrolysis or that prevent RNA from 
stimulating helicase-catalyzed ATP hydrolysis. Because RNA is present in the assay at a 
concentration needed to stimulate ATP hydrolysis to ~85% of its maximal rate, then 
compounds that either inhibit ATP hydrolysis or RNA binding will be identified as “hits”. 
The assay is simpler than other colorimetric phosphate assays based on the Fiske–
SubbaRow method52 or ammonium molybdate reagents that incorporate the dye malachite 
green53, 54 because ATP need not be removed and multiple reagents need not be added in a 
precisely timed procedure.
When the new DENV ATPase HTS assay was used to screen a focused helicase inhibitor 
library composed of compounds reported to inhibit related helicases such as the HCV NS3 
protein,11,35 and more distantly related helicases such as the SV40 Tag protein,55 results 
showed that the assay was robust (high Z′ factor, Figure 1C) and reproducible (Figure 2A). 
The ATPase assay was also more sensitive than unwinding assays in detecting helicase 
inhibitors. As evidence, higher concentrations of compounds were needed to inhibit DENV 
helicase in RNA unwinding assays than were needed to inhibit ATPase assays to the same 
extent. Some compounds that inhibited ATP hydrolysis failed to inhibit RNA unwinding 
even at much higher concentrations (Table 1; Figure 3C).
The most noteworthy of the new DENV helicase inhibitors reported here are a set of 
pyrrolones, which also inhibited the DENV replicon and WNV replication in cell culture 
(Figure 4; Table 3). Unlike other helicase inhibitors detected with the assay, the pyrrolones 
do not inhibit the related HCV helicase under any conditions tested. The pyrrolones were all 
built around a 4-hydroxy-3-(5-methylfuran-2-carbonyl)-2H-pyrrol-5-one scaffold (see the 
Supporting Information for synthesis and characterization). Three of the most potent 
compounds contained a 3,5-dichlorophenyl R1 group with one of three R2 groups. 
Replacement of the chlorines led to a marked decrease in biological activity. In the R2 
position, isoxazole was most active in cells (compound 25), and compounds in which the 
isoxazole was replaced with either a benzyl (compound 26) or a furanylmethyl (compound 
29) were about 3 times more potent inhibitors of DENV helicase-catalyzed ATP hydrolysis 
in vitro.
The other series of DENV helicase inhibitors that was analyzed in this study was composed 
of analogues of NIH molecular probe ML283 (compound 13), which was designed to inhibit 
HCV helicase.31 ML283 is a benzothiazole oligomer that acts by displacing nucleic acids 
from the HCV helicase.35 Our comparison of the effects of these compounds on the DENV 
and HCV helicase yielded several noteworthy results. First, lower concentrations of these 
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compounds inhibit HCV helicase-catalyzed unwinding than are needed to inhibit HCV 
helicase-catalyzed ATP hydrolysis (to the same extent). The reverse is true with DENV 
helicase. Higher concentrations of the compounds are needed to inhibit DENV helicase-
catalyzed unwinding than ATP hydrolysis. Second, some ML283 analogues were better 
inhibitors of DENV helicase than the HCV helicase. The two most potent, compounds 5 
(Table 1) and 24 (Table 2), were >10 times more active against the DENV protein. Although 
most ML283 analogues had some activity against the DENV replicon when tested at 20 μM, 
only compound 24 reduced replication of a subgenomic DENV replicon in cells in a 
concentration-dependent manner (Table 2).
If properly optimized, the two series of compounds reported here could be valuable probes 
to study the role of the helicase in viral replication, and they might lead to new direct-acting 
antivirals. Few direct-acting antiflavivirus agents have been reported, and some that were 
suspected to act via the helicase, such as ivermectin,28 also affect host proteins.56 NS3 is 
one of the most widely studied antiviral drug targets mainly because of the intense emphasis 
on HCV drug discovery. However, most HCV drug discovery has focused on the NS3 
protease function. NS3 proteins are multifunctional, with the N-terminal domain acting as a 
protease needed for viral polyprotein processing and the C-terminal domain acting as a 
helicase. Three NS3 protease inhibitors have recently been approved to treat chronic 
infection with HCV, which is in the same family (Flaviviridae) as the flaviviruses. 
Flaviviridae members encode the only proteins known that are both proteases and helicases. 
The compounds reported here might also prevent flaviviruses from capping their RNA 
because the same site that cleaves ATP also prepares RNA for capping by removing the 5′ 
terminal phosphate from the (+) sense RNA genome.25 Regardless of whether or not the 
new inhibitors here are studied further, the new assays reported here should be valuable 
tools for discovering additional compounds that inhibit the DENV helicase.
METHODS
Protein Expression and Purification
All oligonucleotides were purchased from Integrated DNA Technologies (Coral-ville, IA, 
USA). The helicase domain of dengue virus NS3 (NS3 amino acids 171–618) fused at its N-
terminus to thioredoxin and a (His)6 tag followed by an enterokinase cleavage site was 
expressed and purified in Escherichia coli Rosetta (DE3). A plasmid expressing this protein 
was obtained from Julien Lescar (Singapore),32 and the protein was purified as previously 
described.57
ATP Hydrolysis (ATPase) Assay
Reactions were performed in 30 μL in clear 384-well microplates (Thermonunc), and they 
each contained 25 mM Tris, pH 7.5, 1.25 mM MgCl2, 100 μM ATP, 33 μg/mL BSA, 0.07% 
(v/v) Tween 20, 0.3 mM DTT, 0.6% DMSO, 15 μM poly(U) RNA (expressed as nucleotide 
concentration), and 3 nM DENV NS3h (or 4 nM HCV NS3h). For automated screening, 
reactions containing all components except test compounds and MgCl2 were assembled at 
1.11 times their final concentration. After 27 μL of this reaction mixture was dispensed in 
each well, 200 nL of each test compound (6.67 μM final concentration) or DMSO was added 
Sweeney et al. Page 8













(0.3% DMSO v/v, final). Reactions were initiated by adding 3 μL of 12.5 mM MgCl2. After 
30 min at 23 °C, 50 μL of Biomol Green reagent (Enzo Life Sciences) was added, and after 
a final 30 min of incubation at 23 °C, absorbance at 620 nm was read. Percent inhibition was 
calculated by normalizing the data to assays containing 6.7 μM ATA (100% inhibition) and 
reactions with DMSO only (0% inhibition).
RNA/DNA Unwinding Assay
Molecular beacon-based DNA and RNA unwinding assays were performed as described 
previously with HCV helicase.37 For reactions with DENV helicase, the buffer described for 
ATPase assays (above) and 100 nM DENV was included in each reaction.
DENV Subgenomic Replicon Assay
A total of 258 compounds were screened, 86 in duplicate and 173 in singlicate. Stable baby 
hamster kidney (BHK-21) DENV-Rluc cells41 were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM, LifeTech) containing 4.5 g/L D-glucose, L-glutamine, and 110 
mg/L sodium pyruvate and supplemented with 10% FBS, 100 U/mL each of penicillin and 
streptomycin, and 3 μg/mL puromycin to maintain replicon stability. Cells were grown at 37 
°C and in atmosphere supplemented with 5% CO2. DENV-Rluc cells were seeded in clear 
96-well culture plates (Corning 3599) without puromycin at a concentration of 1000 cells 
per well. Cells were allowed to adhere to the plate for a minimum of 4 h, but not for more 
than 24 h. Compounds dissolved in DMSO were first diluted in DMEM and then added to 
cells such that the final volume in the well was 100 μL, the final DMSO concentration was 
1%, and the final compound concentration was 20 μM. Quadruplicate control wells 
containing DMSO only or 40 μM ribavirin were included on each assay plate. Cells were 
incubated for 72 h at 37 °C and 5% CO2 atmosphere.
The effect of compounds on DENV replication was assessed by measuring Renilla 
luciferase reporter gene activity using a Renilla luciferase assay kit (Promega, Madison, WI, 
USA). Medium was aspirated and cells were washed with PBS before being lysed with 70 
μL of Renilla luciferase lysis buffer. Cells were rocked for 1 h at room temperature, and then 
50 μL of lysate was transferred to a black 96-well luminescence plate (Nunc 9502867). 
Luciferase activity was measured in a FluoSTAR Omega (BMG Labtech, Germany) after 
the injection of 25 μL of luciferase substrate and reading for 10 s. Percent inhibition was 
normalized to DMSO-only controls.
Compounds that inhibited at least 50% and reduced cell viability less than 20% were tested 
again in confirmatory “cherry pick” assays, and those that inhibited confirmatory assays at 
least 50% were assayed in eight-point two-fold concentration–response (from 200 μM to 1.6 
μM final concentrations) to obtain IC50 values.
Cell Viability Assays
To determine compound toxicity, BHK DenV-Rluc cells were plated and treated as above, 
and cell viability was assessed using the CellTiter-Glo luminescent cell viability kit 
(Promega). At the end of 72 h, the medium was aspirated and an equal volume of CellTiter-
Glo reagent and medium was added to each well. After incubation for 30 min at room 
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temperature, luminescence was read for 5 s using a FLUOstar Omega (BMG Labtech, 
Germany) and converted to percentage viability by normalizing readings to those obtained 
from cells treated with DMSO only (i.e., negative controls).
West Nile Virus (Kunjin Subtype) Assay
Effects of compounds on West Nile virus were measured as previously described.8
Data Analysis
Z′ factors were calculated as described by Zhang et al.33 Half-maximal inhibitory 
concentrations were calculated from concentration–response curves using nonlinear 
regression to fit data to a log(inhibitor) versus normalized response equation with variable 
slope. Therapeutic index (TI) was defined as CC50/EC50.
Instant JChem 6.0 (2013) was used for structure database management, search, and 
prediction (ChemAxon (http://www.chemaxon.com).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS
ATA aurintricarboxylic acid
BHK baby hamster kidney
HCV hepatitis C virus
HTS high-throughput screen
DENV Dengue virus
NS3h nonstructural protein 2 lacking the protease domain
WNV West Nile virus
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DENV helicase high-throughput ATPase assay. (A) Assay setup. DENV helicase (gray) 
cleaves ATP at a slow basal rate (kslow) and more rapidly in the presence of RNA (kfast). The 
Biomol Green reagent reacts with inorganic phosphate to produce a product that absorbs 
light at 620 nm. In automated screening, compounds are added to a reaction mix, and ATP 
hydrolysis is initiated with Mg2+. In addition to key reagents noted, all assays were 
performed at pH 7.5 and contained 5 μg/mL BSA, 0.01% (v/v) Tween 20, 5 mM DTT, and 
0.3% DMSO (final concentration). (B) Effect of poly(U) RNA on inorganic phosphate 
released from ATP in the presence of 2 nM DENV NS3h after indicated times. Conditions 
with the best signal compared to control assays where reactions were not initiated with 
MgCl2 were chosen for HTS. (C) To assess assay quality, a Z′ factor33 was calculated by 
performing 192 positive control reactions (7 μM aurintricarboxylic acid (ATA)) and 192 
negative control reactions (DMSO only) arranged in a checkerboard fashion in a 384-well 
plate. (D) Concentration–response assays using nonspecific helicase inhibitors.11, 34
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Screen of a focused helicase inhibitor library (A) Each compound was tested twice, and the 
result from the first assay (x-axis) was compared to the result from the second (y-axis) to 
assess assay reproducibility. (B) Concentration–response assays with selected inhibitors in 
the benzothiazole class. (C) Concentration–response assays with representatives of the 
pyrrolone class of compounds. In panels B and C results are compared with data obtained 
with the potent nonspecific helicase inhibitor ATA (dotted lines).
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Ability of hit compounds to inhibit DENV helicase-catalyzed RNA strand separation. (A) In 
the assay, the helicase loads on the 3′ single-stranded tail of the substrate, and translocates 3′ 
to 5′ upon addition of ATP to separate a Cy5-labeled annealed RNA strand from an 
annealed DNA strand labeled with the fluorescence quencher Iowa black RQ (IAbRQ, 
Integrated DNA Technologies).12,37 (B) Concentration-dependent inhibition of DENV 
helicase-catalyzed RNA unwinding by ML283 (compound 13). Fluorescence traces with 
only three ML283 concentrations are shown for clarity. (C) Concentration–response plots 
obtained for select inhibitors. Activity was normalized by first calculating initial rates of 
fluorescence increase and then normalizing these rates to those observed in negative control 
reactions containing DMSO alone. IC50 values obtained by fitting data with GraphPad 
PRISM are shown in Table 1.
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Effects of helicase inhibitors on cellular flavivirus replication. (A) Subgenomic DENV 
replicon used in this study. (B) Percent of DENV replicon remaining in cells treated with 20 
μM of each compound in the focused helicase inhibitor library plotted against the effect of 
20 μM of each compound on cell viability. Dotted lines mark arbitrary cutoffs. (C) Effects of 
compounds in Tables 2 and 3 on DENV replicon content and cell viability (av ± SD, n = 3). 
(D) Effect of various concentrations of 25 on cell viability (+) and subgenomic replicon 
(sgR) content (○). (E) BHK cells were infected with West Nile virus in the presence of 50 
μM of indicated compounds and titered 72 h later (av ± SD, n = 3). (F) Effect of various 
concentrations of compound 25 on West Nile virus titers (av ± SD, n = 3).
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Table 2
ML283 Analogue with Optimal Antiviral Activity in Cells
compd (CID) DENV ATPase IC50a (μM) DENV helicase IC50a (μM) replicon EC50b (μM) TIc
24 (49849289) 0.5 ± 0.1 1.5 ± 0.2 7.1±3 17
a
As defined in Table 1.
b
Half-maximal inhibitory concentration observed in assays monitoring BHK cell DENV replicon content.
c
Half-maximal inhibitory concentration observed in BHK cell viability assays (CC50)/replicon EC50.
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Table 3
DENV Helicase Inhibitors Active against DENV Replicons but Not the HCV Helicase
Cmpd (CID) R1, R2 ATPase IC50 (μM)a Replicon EC50 (μM)b T.I.b
25 (45382104)   78±23 36±6 4.5
26 (45382103) 27±8   59±14 3.5
27 (4594423) 147±72   60±21 5.4
28 (45382102)   93±25 104±48 2.1
29 (4473963) 30±8 125±93 2.0
30 (45382099) 29±9 147±38 7.2
a
As defined in Table 1.
b
As defined in Table 2.
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